Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Altum Sequencing logo — Following the genetic trail of cancer

Altum Sequencing

Following the genetic trail of cancer

Founded 2019 Spain Spain 17 employees Analytics, Biotechnology

General Information

Company Name Altum Sequencing
Founded Year 2019
Location Spain Spain
Employees 17
Industries Analytics, Biotechnology
Business Model B2B, B2C, D2C
Revenue Model Service Fee, Usage Based, Transaction Fee
Social

BounceWatch is an independent company data service, not affiliated with Altum Sequencing. To contact Altum Sequencing, visit altumsequencing.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Altum Sequencing compare?

A PDF of Altum Sequencing and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Altum Sequencing soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Altum Sequencing

Altum Sequencing, founded in 2019, operates at the cutting edge of the Analytics and Biotechnology industries. With headquarters in Spain, it is strategically positioned within a thriving European biotech sector.

The company's slogan, "Following the genetic trail of cancer," succinctly encapsulates its mission to revolutionize cancer monitoring. Altum Sequencing focuses on enabling better decision-making for clinicians and providing detailed insights into disease progression for patients.

Altum Sequencing secured support from healthstart madri+d during its last investment round on 01 January 2022. This backing underscores investor confidence in their innovative approach to cancer cell monitoring.

Their focus on improving treatment outcomes for clinicians and patients alike makes Altum Sequencing a promising endeavor for potential stakeholders looking to invest in the future of personalized healthcare solutions.

Business keywords: Cancer Cell Monitoring, Liquid Biopsy, Cancer Therapy Guidance, Minimal Residual Disease, ClonEv®, High Sensitivity Testing, Cost Efficiency, Cancer Relapse Detection, Clinical Trial Endpoints, Tumor Cell Detection, Cancer Diagnostics, Next-Generation Sequencing, Molecular Services, Bioinformatics

Services & Products

Liquid Biopsy Tests
MRD Monitoring
Molecular Tumor Profiling
Gene Fusions Detection
Single Nucleotide Variation Detection
Gene Expression Analysis
Microsatellite Instability Analysis
Whole Genome/Exome Sequencing

Target Customers

Clinicians Cancer Patients Biopharma Companies Researchers Healthcare Professionals

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Support Program Undisclosed 1
healthstart madri+d
01 Jan 2022
Spinout Undisclosed 2
Hospital 12 de Octubre Research Institute, Hospital 12 de Octubre
01 Dec 2019

Altum Sequencing Alternatives & Competitors

View All Alternatives
Altum Sequencing vs
Personal Genome Diagnostics
Personal Genome Diagnostics

Leading the way in patient-specific cancer genome analysis with groundbreaking technologies for non-...

Series C
0-1 employees
Analytics, Biotechnology
Altum Sequencing vs
GENOME INSIGHT INC.
GENOME INSIGHT INC. United States

Cancer whole genome platform company

Series B
54 employees
Analytics, Biotechnology
Compare Altum Sequencing vs GENOME INSIGHT INC.
Altum Sequencing vs
Geninus Inc.
Geninus Inc. Korea South

Living better with your DNA

Venture round
57 employees
Analytics, Biotechnology
View all alternatives

FAQ About Altum Sequencing

Following the genetic trail of cancer
Altum Sequencing was founded in 2019.
Altum Sequencing is headquartered in Spain.
Altum Sequencing operates in Analytics and Biotechnology. Its work centres on Cancer Cell Monitoring, Liquid Biopsy, Cancer Therapy Guidance and Minimal Residual Disease. Its customers include Clinicians, Cancer Patients and Biopharma Companies.
Altum Sequencing has a B2B, B2C and D2C business model. Its revenue comes from Service Fee, Usage Based and Transaction Fee.
Altum Sequencing has approximately 17 employees.
Altum Sequencing has completed 2 funding rounds.
Altum Sequencing offers: Liquid Biopsy Tests, MRD Monitoring, Molecular Tumor Profiling, Gene Fusions Detection, Single Nucleotide Variation Detection, Gene Expression Analysis, Microsatellite Instability Analysis, Whole Genome/Exome Sequencing, RNA-Seq and Methylation Sequencing.
Top alternatives and competitors to Altum Sequencing include Personal Genome Diagnostics, GENOME INSIGHT INC., Geninus Inc. . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Altum Sequencing and Personal Genome Diagnostics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Altum Sequencing, https://bouncewatch.com/company/altum-sequencing, updated 13 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes